Aclarion (Aclarion) Accounts Receivable : $0.02 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Aclarion Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Aclarion's accounts receivables for the quarter that ended in Mar. 2024 was $0.02 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Aclarion's Days Sales Outstanding for the quarter that ended in Mar. 2024 was 155.13.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Aclarion's Net-Net Working Capital per share for the quarter that ended in Mar. 2024 was $0.13.

Aclarion Accounts Receivable Historical Data

The historical data trend for Aclarion's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclarion Accounts Receivable Chart

Aclarion Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

0.02

0.01

0.02

0.01

Aclarion Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Receivable	Get a 7-Day Free Trial											0.02	0.01	0.02	0.01	0.02

Aclarion Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Aclarion Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Aclarion's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.017	/	0.01	*	91
=	155.13

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Aclarion's accounts receivable are only considered to be worth 75% of book value:

Aclarion's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(2.133	+	0.75 * 0.017	+	0.5 * 0	-	1.222
-	0	-	0)	/	7.1535
=	0.13

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Aclarion Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Aclarion's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclarion (Aclarion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Aclarion Inc (NAS:ACON) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

8181 Arista Place, Suite 300, Broomfield, CO, USA, 80021

Website

http://www.aclarion.com

Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.

Executives

John Paul Lorbiecki	officer: Chief Financial Officer	238 CHEYENNE DRIVE, LAFAYETTE CO 80026
Brent Ness	director, officer: Chief Executive Officer	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Ryan Bond	officer: Chief Strategy Officer	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
Stephen Deitsch	director	1600 BROADWAY, SUITE 700, DENVER CO 80202
William Wesemann	director	130 MONTALVO ROAD, REDWOOD CITY CA 94062
Jeffrey John Thramann	director, officer: Executive Chairman	8580 STRAWBERRY LANE, NIWOT CO 80503
Michael W Dirks	10 percent owner	811 EAST 30TH AVE, HUTCHINSON KS 67502
Nuvasive Inc	10 percent owner	7475 LUSK BLVD, SAN DIEGO CA 92121
Sc Capital 1 Llc	10 percent owner	1 COMPOUND DRIVE, HUTCHINSON KS 67502
Scott Breidbart	director	951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404
Amanda Mae Sequira	director	951 MARINERS ISLAND BLVD., SUITE 300, SAN MATEO CA 94404
David K Neal	director	C/O ACLARION, INC., 951 MARINERS ISLAND BLVD, SUITE 300, SAN MATEO CA 94404